ArticleDigestive diseases and sciences2026
High-Dose Opioid Use Among Adolescents and Young Adults with Chronic Digestive Disorders.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHigh-dose opioid use (≥ 50 morphine milligram equivalents [MME]/day) is associated with increased risk of adverse outcomes, including overdose. We investigated the prevalence and risk factors for high-dose opioid use among adolescents and young adults (AYA) with inflammatory bowel disease (IBD) and other chronic digestive disorders to inform safer pain management strategies.
methodsThis retrospective cohort study identified AYA aged 15-29 years with chronic digestive disorders who received ≥ 1 outpatient opioid prescription between March 2018 and December 2021, using Northwestern Medicine's Electronic Data Warehouse. Short-term persistent high-dose opioid use was defined as a daily mean of ≥ 50 MME/day for ≥ 7 consecutive days. Patients were categorized into high-dose vs. non-high-dose users. We examined demographic and clinical covariates (e.g., race/ethnicity, insurance status, psychiatric diagnoses, GI and non-GI pain diagnoses, concurrent medications) using descriptive and bivariate analyses. Risk factors for high-dose use were identified via multivariate logistic regression.
resultsAmong 2549 AYA patients, 12% met criteria for high-dose opioid use. Risk factors included older age within the cohort, benzodiazepine-opioid co-use, oxycodone use, and concurrent non-GI pain diagnoses (e.g., arthritis). DISCUSSION: Nearly 12% of AYA with chronic digestive disorders who used opioids for ≥ 7 days received high-dose prescriptions. These findings underscore the need for safer prescribing guidelines tailored to this population. Future work should consider weight-based dosing thresholds and expanded datasets to monitor and reduce opioid-related harm in AYA with digestive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.